Hyaluronic acid-coated liposomes for active targeting of gemcitabine

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 373-380

  Arpicco, Silvia ^a   Lerda, Carlotta ^a   Dalla Pozza, Elisa ^b   Costanzo, Chiara ^b   Tsapis, Nicolas ^c   Stella, Barbara ^a   Donadelli, Massimo ^b   Dando, Ilaria ^b   Fattal, Elias ^c   Cattel, Luigi ^a   Palmieri, Marta ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIV PARIS SUD   (France)

Author keywords

Active targeting; CD44; Gemcitabine; Hyaluronic acid; Liposomes; Pancreatic cancer

Indexed keywords

CELL SURFACE RECEPTOR; CELL SURFACE RECEPTOR CD44; GEMCITABINE; HYALURONIC ACID; LIPOSOME; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG FORMULATION; ENCAPSULATION; HUMAN; HUMAN CELL; LIPOPHILICITY; MOLECULAR WEIGHT; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ACTIVE TARGETING; CD44; GEMCITABINE; HYALURONIC ACID; LIPOSOMES; PANCREATIC CANCER;

ADENOCARCINOMA; ANTIGENS, CD44; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; LIPOSOMES; MOLECULAR WEIGHT; PANCREATIC NEOPLASMS; PHOSPHATIDYLETHANOLAMINES; PRODRUGS;

EID: 84888362147     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.06.003     Document Type: Article

References (44)

1. L.W. Hertel, J.S. Kroin, J.W. Misner, and J.M. Tustin Synthesis of 2-deoxy-2,2-difluoro-d-ribose and 2-deoxy-2,2-difluoro-d-ribofuranosyl nucleosides Journal of Organic Chemistry 53 1988 2406 2409
2. L.W. Hertel, G.B. Boder, J.S. Kroin, S.M. Rinzel, G.A. Poore, G.C. Todd, and G.B. Grindey Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate - a mechanism of self-potentiation Cancer Research 50 1990 4417 4422
3. W. Plunkett, P. Huang, and V. Gandhi Preclinical characteristics of gemcitabine Anti-Cancer Drugs 6 1995 7 13
4. V. Heinemann Gemcitabine: progress in the treatment of pancreatic cancer Oncology 60 2001 8 18
5. W. Plunkett, P. Huang, C.E. Searcy, and V. Gandhi Gemcitabine: preclinical pharmacology and mechanisms of action Seminars in Oncology 23 1996 3 15
6. W. Plunkett, P. Huang, Y.Z. Xu, V. Heinemann, R. Grunewald, and V. Gandhi Gemcitabine - metabolism, mechanisms of action, and self-potentiation Seminars in Oncology 22 1995 3 10
7. V. Heinemann, Y.Z. Xu, S. Chubb, A. Sen, L.W. Hertel, G.B. Grindey, and W. Plunkett Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate - a mechanism of self-potentiation Cancer Research 52 1992 533 539
8. D.Y. Bouffard, J. Laliberte, and R.L. Momparler Kinetic-studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase Biochemical Pharmacology 45 1993 1857 1861
9. A. Matsuda, and T. Sasaki Antitumor activity of sugar-modified cytosine nucleosides Cancer Science 95 2004 105 111
10. J.L. Abbruzzese, R. Grunewald, E.A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, M.N. Raber, and W. Plunkett A phase-I clinical, plasma, and cellular pharmacology study of gemcitabine Journal of Clinical Oncology 9 1991 491 498
11. R. Grunewald, H. Kantarjian, M. Du, K. Faucher, P. Tarassoff, and W. Plunkett Gemcitabine in leukemia - a phase-I clinical, plasma, and cellular pharmacology study Journal of Clinical Oncology 10 1992 406 413
12. A.M. Storniolo, S.R.B. Allerheiligen, and H.L. Pearce Preclinical, pharmacologic, and phase I studies of gemcitabine Seminars in Oncology 24 1997 S2 S7
13. B. Pili, L.H. Reddy, C. Bourgaux, S. Lepetre-Mouelhi, D. Desmaele, and P. Couvreur Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation Nanoscale 2 2010 1521 1526
14. D. Paolino, D. Cosco, L. Racanicchi, E. Trapasso, C. Celia, M. Iannone, E. Puxeddu, G. Costante, S. Filetti, D. Russo, and M. Fresta Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR (R): biodistribution, pharmacokinetic features and in vivo antitumor activity Journal of Controlled Release 144 2010 144 150
15. P. Jantscheff, V. Ziroli, N. Esser, R. Graeser, J. Kluth, A. Sukolinskaya, L.A. Taylor, C. Unger, and U. Massing Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model Clinical & Experimental Metastasis 26 2009 981 992
16. I.-Y. Kim, Y.-S. Kang, D.S. Lee, H.-J. Park, E.-K. Choi, Y.-K. Oh, H.-J. Son, and J.-S. Kim Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice Journal of Controlled Release 140 2009 55 60
17. P. Jantscheff, N. Esser, R. Graeser, V. Ziroli, J. Kluth, C. Unger, and U. Massing Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts Prostate 69 2009 1151 1163
18. M.L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs Journal of Controlled Release 100 2004 331 346
19. P. Brusa, M.L. Immordino, F. Rocco, and L. Cattel Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs Anticancer Research 27 2007 195 199
20. B.P. Toole, T.N. Wight, and M.I. Tammi Hyaluronan-cell interactions in cancer and vascular disease Journal of Biological Chemistry 277 2002 4593 4596
21. M. Zoller CD44 - physiological expression of distinct isoforms as evidence for organ-specific metastasis formation Journal of Molecular Medicine - JMM 73 1995 425 438
22. R.J.S. Sneath, and D.C. Mangham The normal structure and function of CD44 and its role in neoplasia Journal of Clinical Pathology - Molecular Pathology 51 1998 191 200
23. B.F. Chong, L.M. Blank, R. McLaughlin, and L.K. Nielsen Microbial hyaluronic acid production Applied Microbiology and Biotechnology 66 2005 341 351
24. J.R.E. Fraser, T.C. Laurent, and U.B.G. Laurent Hyaluronan: its nature, distribution, functions and turnover Journal of Internal Medicine 242 1997 27 33
25. E.A. Balazs Therapeutic use of hyaluronan Structural Chemistry 20 2009 341 349
26. D. Peer, and R. Margalit Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models International Journal of Cancer 108 2004 780 789
27. R.E. Eliaz, and F.C. Szoka Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells Cancer Research 61 2001 2592 2601
28. D. Ruhela, K. Riviere, and F.C. Szoka Efficient synthesis of an aldehyde functionalized hyaluronic acid and its application in the preparation of hyaluronan-lipid conjugates Bioconjugate Chemistry 17 2006 1360 1363
29. G.R. Bartlett Phosphorus assay in column chromatography The Journal of Biological Chemistry 234 1959 466 468
30. T. Bitter, and H.M. Muir A modified uronic acid carbazole reaction Analytical Biochemistry 4 1962 330 334
31. D.S. Dalpathado, H. Jiang, M.A. Kater, and H. Desaire Reductive amination of carbohydrates using NaBH(OAc)(3) Analytical and Bioanalytical Chemistry 381 2005 1130 1137
32. C.F. Nutaitis, and G.W. Gribble Chemoselective reduction of aldehydes with tetra-n-butylammonium triacetoxyborohydride Tetrahedron Letters 24 1983 4287 4290
33. C.G. Gaete, N. Tsapis, L. Silva, C. Bourgaux, and E. Fattal Morphology, structure and supramolecular organization of hybrid 1,2-dipalmitoyl-sn-glycero- 3-phosphatidylcholine-hyaluronic acid microparticles prepared by spray drying European Journal of Pharmaceutical Sciences 34 2008 12 21
34. K. Lohner Effects of small organic-molecules on phospholipid phase transitions Chemistry and Physics of Lipids 57 1991 341 362
35. R.A. Videira, M.C. Antunes-Madeira, and V.M.C. Madeira Biophysical perturbations induced by ethylazinphos in lipid membranes Chemistry and Physics of Lipids 97 1999 139 153
36. A. Kostecka-Gugala, D. Latowski, and K. Strzalka Thermotropic phase behaviour of alpha-dipalmitoylphosphatidylcholine multibilayers is influenced to various extents by carotenoids containing different structural features - evidence from differential scanning calorimetry Biochimica Et Biophysica Acta - Biomembranes 1609 2003 193 202
37. F. Korkmaz, and F. Severcan Effect of progesterone on DPPC membrane: evidence for lateral phase separation and inverse action in lipid dynamics Archives of Biochemistry and Biophysics 440 2005 141 147
38. M. Engelke, S. Tykhonova, M. Zorn-Kruppa, and H. Diehl Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407 Pharmacology and Toxicology 91 2002 13 21
39. I.V. Zhigaltsev, N. Maurer, K. Edwards, G. Karlsson, and P.R. Cullis Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention Journal of Controlled Release 110 2006 378 386
40. S. Anabousi, M. Laue, C.M. Lehr, U. Bakowsky, and C. Ehrhardt Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy European Journal of Pharmaceutics and Biopharmaceutics 60 2005 295 303
41. H.S.S. Qhattal, and X.L. Liu Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes Molecular Pharmaceutics 8 2001 1233 1246
42. D. Peer, and R. Margalit Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models Neoplasia 6 2004 343 353
43. B.P. Toole Hyaluronan in morphogenesis Journal of Internal Medicine 242 1997 35 40
44. P.A.G. McCourt, B. Ek, N. Forsberg, and S. Gustafson Intercellular- adhesion molecule-1 is a cell-surface receptor for hyaluronan Journal of Biological Chemistry 269 1994 30081 30084